Three Years as Editor-in-Chief

Progress in Cardiovascular Diseases

Volumn 59, Issue 4, 2017, Pages 417-418

  Lavie, Carl J ^a  

^a UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

CARDIOLOGY; CARDIOVASCULAR DISEASE; EDITOR; EDITORIAL; EXERCISE; HUMAN; MEDICAL LITERATURE; OBESITY; PHYSICAL ACTIVITY; ART; LEADERSHIP; PUBLICATION;

CARDIOLOGY; CARDIOVASCULAR DISEASES; HUMANS; LEADERSHIP; PERIODICALS AS TOPIC;

EID: 85013428005     PISSN: 00330620     EISSN: 18731740     Source Type: Journal    
DOI: 10.1016/j.pcad.2016.12.004     Document Type: Editorial

References (28)

1. 1. Lavie, C.J., Special commentary-special editor's page — two years as editor-in-chief. Prog Cardiovasc Dis 58 (2016), 461–462.
2. 2. Lavie, C.J., Analyzing 2015 impact factors — special editor's commentary. Prog Cardiovasc Dis 59 (2016), 323–324.
3. 3. Arena, R., Despres, J.-P.A., Message from modern-day health care to physical activity and fitness: welcome home. Prog Cardiovasc Dis 57 (2015), 293–295.
4. 4. Myers, J., McAuley, P., Lavie, C.J., et al. Physical activity and cardiorespiratory fitness as major markers of cardiovascular risk: their independent and interwoven importance to health status. Prog Cardiovasc Dis 57 (2015), 306–314.
5. 5. DeFina, L.F., Haskell, W.L., Willis, B.L., et al. Physical activity versus cardiorespiratory fitness: two (partly) distinct components of cardiovascular health?. Prog Cardiovasc Dis 57 (2015), 324–329.
6. 6. Carlson, S.A., Fulton, J.E., Pratt, M., Yang, Z., Adams, E.K., Inadequate physical activity and health care expenditures in the United States. Prog Cardiovasc Dis 57 (2015), 315–323.
7. 7. Pratt, M., Perez, L.G., Goenka, S., et al. Can population levels of physical activity be increased? Global evidence and experience. Prog Cardiovasc Dis 57 (2015), 356–367.
8. 8. Sallis, R., Franklin, B., Joy, L., et al. Strategies for promoting physical activity in clinical practice. Prog Cardiovasc Dis 57 (2015), 375–386.
9. 9. O'Keefe, J.H., Lavie, C.J., Guazzi, M., Part 1: potential dangers of extreme endurance exercise: how much is too much? Part 2: screening of school-age athletes. Prog Cardiovasc Dis 57 (2015), 396–405.
10. 10. Morin, D.P., Estes, M. III, Advances in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis 58 (2015), 103–104.
11. 11. Sheikh, A., Patel, N.J., Nalluri, N., et al. Trends in hospitalization for atrial fibrillation: epidemiology, cost, and implications for the future. Prog Cardiovasc Dis 58 (2015), 105–116.
12. 12. Menezes, A.R., Lavie, C.J., De Schutter, A., et al. Lifestyle modification in the prevention and treatment of atrial fibrillation. Prog Cardiovasc Dis 58 (2015), 117–125.
13. 13. Thihalolipavan, S., Morin, D.P., Atrial fibrillation and heart failure: update 2015. Prog Cardiovasc Dis 58 (2015), 126–135.
14. 14. Waldo, A.L., Rate control versus rhythm control in atrial fibrillation: lessons learned from clinical trials of atrial fibrillation. Prog Cardiovasc Dis 58 (2015), 168–176.
15. 15. Gerstenfeld, E.P., Duggirala, S., Atrial fibrillation ablation: indications, emerging techniques, and follow-up. Prog Cardiovasc Dis 58 (2015), 202–212.
16. 16. Kumar, P., Kiser, A.C., Gehi, A.K., Hybrid treatment of atrial fibrillation. Prog Cardiovasc Dis 58 (2015), 213–220.
17. 17. Morin, D.P., Bernard, J.L., Madias, C., et al. The state of the art: atrial fibrillation epidemiology, prevention, and treatment. Mayo Clin Proc 91 (2016), 1778–1810.
18. 18. Ortega, F.B., Cadenas-Sanchez, C., Sui, X., et al. Role of fitness in the metabolically healthy but obese phenotype: a review and update. Prog Cardiovasc Dis 58 (2015), 76–86.
19. 19. Joseph, L., Robinson, J.G., Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibition and the future of lipid lowering therapy. Prog Cardiovasc Dis 58 (2015), 19–31.
20. 20. Lavie, C.J., Sharma, A., Alpert, M.A., et al. Update on obesity and obesity paradox in heart failure. Prog Cardiovasc Dis 58 (2016), 393–400.
21. 21. Lavie, C.J., De Schutter, A., Parto, P., et al. Obesity and prevalence of cardiovascular diseases and prognosis — the obesity paradox updated. Prog Cardiovasc Dis 58 (2016), 537–547.
22. 22. DiNicolantonio, J.J., Lucan, S.C., O'Keefe, J.H., The evidence for saturated fat and for sugar related to coronary heart disease. Prog Cardiovasc Dis 58 (2016), 464–472.
23. 23. O'Keefe, E.L., DiNicolantonio, J.J., Patil, H., et al. Lifestyle choices fuel epidemics of diabetes and cardiovascular disease among Asian Indians. Prog Cardiovasc Dis 58 (2016), 505–513.
24. 24. DiNicolantonio, J.J., O'Keefe, J.H., Hypertension due to toxic white crystals in the diet: should we blame salt or sugar?. Prog Cardiovasc Dis 59 (2016), 219–225.
25. 25. Oktay, A.A., Lavie, C.J., Milani, R.V., et al. Current perspectives on left ventricular geometry in systemic hypertension. Prog Cardiovasc Dis 59 (2016), 235–246.
26. 26. Milani, R.V., Lavie, C.J., Wilt, J.K., et al. New concepts in hypertension management: a population-based perspective. Prog Cardiovasc Dis 59 (2016), 289–294.
27. 27. Reilly, J.P., White, C.J., Renal denervation for resistant hypertension. Prog Cardiovasc Dis 59 (2016), 295–302.
28. 28. Kario, K., Evidence and perspectives on the 24-hour management of hypertension: hemodynamic biomarker-initiated ‘anticipation medicine’ for zero cardiovascular event. Prog Cardiovasc Dis 59 (2016), 262–281.